
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences is a leader in the transcatheter valve solutions market and has seen strong growth in its key business segments, including TAVR and TMTT. The proposed NCD from CMS is expected to remove barriers and drive higher procedure volumes, while the company's strong clinical evidence and technological leadership position it for continued growth. Additionally, EW's commitment to diversity and inclusion, multiple shots on goal with clinical works in progress, and potential for market expansion in the MR space make it a compelling investment opportunity with potential for upside in the long term.
Bears say
Edwards Lifesciences is a leader in the structural heart disease market, driven by its solid product portfolio and upcoming market-expanding catalysts. However, potential commercial hiccups, regulatory delays, product recalls, and competition pose risks to its future growth. Additionally, concerns about valve durability and lack of sustainability initiatives may weigh on investor sentiment.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares